5 results about "Varices" patented technology

V1a RECEPTOR PARTIAL AGONISTS AND METHODS OF USE SOLUTION: The present invention provides novel partial V1a agonists for partial activation of V1a receptors. The partial V1a agonists have therapeutic indices of at least 20 (e.g., at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100). Also provided is a method of treating liver fibrosis, hepatocirrhosis, portal hypertension, peritoneal fluid, esophageal varices, fundic varices, hemorrhage, arterial hypotension, and / or hepatorenal syndrome, comprising administering to a subject in need thereof a therapeutically effective dose of a composition comprising one or more of the disclosed partial V1a agonists, optionally in combination with a V2 antagonist.SELECTED DRAWING: None

The application discloses a medical tissue glue modified formula and injection method for treating esophageal varices, and relates to the field of tissue glue; the medical tissue glue modified formula and injection method for treating esophageal varices introduce polyoxyl glycol as a modifier, not only reduce the brittleness and hardness of n-butyl alpha-cyanoacrylate after polymerization, make the formed vascular embolus more flexible, significantly reduce the cutting risk of traditional hard glue block to thin-walled mucosa, thereby reduce the incidence of postoperative glue leakage ulcer and rebleeding; at the same time, polyoxyl glycol itself as a hardener can synergistically damage the vascular endothelium, accelerate thrombosis and vascular fibrosis, and improve the long-term occlusion effect; secondly, the addition of dragon's blood extract or nano-silver and other antibacterial components in the formula can actively inhibit local bacterial colonization, effectively reduce the risk of postoperative sepsis for the clinical pain points of low immunity and easy infection of patients with cirrhosis.

The present disclosure provides novel V1a partial agonists for partially activating a V1a receptor. The partial V1a agonist has a therapeutic index of at least 20 (e.g., at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100). Also provided are method of treating liver fibrosis, cirrhosis, portal hypertension, ascites, esophageal varices, fundal varices, bleeding, arterial hypotension, and / or hepatorenal syndrome, including administering to a subject in need thereof a therapeutically effective dose of a composition including the V1a partial agonist(s) of the present disclosure, optionally in combination with a V2 antagonist.

The utility model discloses an auxiliary positioning transparent cap for esophageal varicosity endoscopic injection, which is characterized in that a clamping groove is arranged on the side wall of the transparent cap, and the side wall of the clamping groove is of an arc-shaped structure; according to the invention, the surgical operation becomes simple and accurate, and the success rate and curative effect of the surgery are improved.

Sclerosing agent for use in treating a varicose, reticular or spider vein, wherein the sclerosing agent is administered in a formulation further comprising a water-soluble cellulose derivative, pharmaceutical composition comprising a sclerosing agent and a water-soluble cellulose derivative as well as a kit or a method for producing a foam comprising a sclerosing agent and a water-soluble cellulose derivative.